Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950461 | 0.83 | ESR1 (0.46) | ALDH1A1HRH3 | |
| SCHEMBL6935441 | 0.83 | LMNA (0.49) | ALDH1A1AOC3CA1CA2CA12 | |
| SCHEMBL19148146 | 0.81 | AOC3 (0.61) | ALDH1A1AOC3CA1CA2CA12 | |
| SCHEMBL7130084 | 0.81 | AOC3 (0.61) | ALDH1A1AOC3CA1CA2CA12 | |
| SCHEMBL3923688 | 0.79 | AOC3 (0.50) | ALDH1A1AOC3CA1CA2CA12 | |
| SCHEMBL5666707 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CA1CA2SMN1; SMN2 | |
| SCHEMBL15076967 | 0.78 | HRH3 (0.63) | ALDH1A1HRH3LMNAHTTSMN1; SMN2 | |
| SCHEMBL25955803 | 0.77 | ESR1 (0.54) | ALDH1A1AOC3CA1CA2CA12 | |
| SCHEMBL25489527 | 0.77 | CA1 (0.58) | ALDH1A1AOC3CA1CA2CA12 | |
| SCHEMBL812742 | 0.77 | CA1 (0.58) | ALDH1A1AOC3CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236113-B2 | Hydrocarbon-soluble halogen and thiolate/magnesium exchange reagents | ALBEMARLE GERMANY GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20200239496-A1 | Hydrocarbon-Soluble Halogen and Thiolate/Magnesium Exchange Reagents | Ludwig-Maximilians-Universitat München (DE) | 2020-07-30 | — | — | US | disclosed |
| WO-2019063418-A1 | HYDROCARBON-SOLUBLE HALOGEN AND THIOLATE/MAGNESIUM EXCHANGE REAGENTS | ALBEMARLE GERMANY GMBH (DE) | 2019-04-04 | — | — | WO | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060293385-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-12-28 | — | — | US | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1687265-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051898-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239496-A1 | Hydrocarbon-Soluble Halogen and Thiolate/Magnesium Exchange Reagents | OR10J3, MSRB3, SLC39A3 | ALDH1A1 2020/4885AOC3 44/4885CA1 887/4885 |
| US-20060293385-A1 | Vitamin d receptor modulators | VDR, CYP24A1, CYP2R1 | ALDH1A1 2756/4885AOC3 4620/4885CA1 2762/4885 |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | ALDH1A1 2371/4885AOC3 4484/4885CA1 4410/4885 |
| US-11236113-B2 | Hydrocarbon-soluble halogen and thiolate/magnesium exchange reagents | MSRB3, OR10J3, GFER | ALDH1A1 2179/4885AOC3 67/4885CA1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.